Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836132 | 0.98 | MAPT (0.48) | ALDH1A1MAPTNPSR1HIF1AKDM4E | |
| SCHEMBL2370495 | 0.87 | HDAC3 (0.48) | ALDH1A1MAPTKDM4EGFERNPC1 | |
| SCHEMBL1038565 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPTHIF1AKDM4EHTT | |
| SCHEMBL5358916 | 0.81 | CNR2 (0.45) | ALDH1A1MAPTNPSR1HIF1AKDM4E | |
| SCHEMBL5512244 | 0.79 | HRH3 (0.52) | ALDH1A1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL22504111 | 0.78 | CNR2 (0.42) | ALDH1A1MAPTNPSR1HIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL5877923 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTNPSR1KDM4EHTT | |
| SCHEMBL24136303 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MAPTNPSR1HIF1AKDM4E | |
| SCHEMBL27346732 | 0.76 | ALDH1A1 (0.49) | ALDH1A1MAPTNPSR1KDM4EGFER | |
| SCHEMBL27565323 | 0.76 | ALDH1A1 (0.53) | ALDH1A1MAPTNPSR1HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212155-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2011034849-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMED PHARMA, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | ALDH1A1 1414/4885MAPT 51/4885NPSR1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.